Latest Videos Archives

Adapting European Association of Urology (EAU) Guidelines Recommendations in the Era of COVID-19

Posted by Theo M. de Reijke, MD, PhD, FEBU | Apr 2020

Theo M. de Reijke, MD, PhD, FEBU, Associate Professor of Urology at the University of Amsterdam, discusses the new European Association of Urology (EAU) guidelines on how to care for patients during the COVID-19 pandemic. He goes on to explain how older EAU recommendations, which are currently being implemented by practices, can have major impacts on how urologists and hospitals care for patients during COVID-19, and how the updated guidelines aim to solve some of the treatment and diagnostic dilemmas caused by the pandemic. Finally, Dr. de Reijke notes the regional nature of these recommendations, and how different countries may have different rules and recommendations in place regarding the diagnosis of COVID-19 among patient populations, as well as differences in guidelines regarding the utilization of personal protective equipment.

Safely Managing a Radiation Oncology Clinic in the Age of COVID-19

Posted by Steven E. Finkelstein, MD, FACRO | Apr 2020

Steven E. Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates in Panama City, Florida, provides guidance on how to safely manage a radiation oncology clinic during the COVID-19 crisis. He explains that it is important to screen patients for COVID-19 symptoms before treatments, and emphasizes that staff must be trained in how to safely work with potentially infected individuals. Noting that every practice will have to plan differently depending on its resources and the population it serves, Dr. Finkelstein also discusses how practices might minimize the number of patients seen, i.e. by deferring radiation treatments for prostate cancer in favor of increased duration of neoadjuvant ADT or active surveillance when appropriate. He observes that while alternatives to traditional radiation oncology like seed implantation could minimize clinic visits, many practices currently lack the resources to implement brachytherapy.

Telemedicine for Seniors

Posted by Neil H. Baum, MD | Apr 2020

Neil H. Baum, MD, Professor of Clinical Urology at Tulane Medical School, discusses how much COVID-19 has changed the demand for telemedicine, particularly for seniors who are considered more at-risk, and therefore need to avoid clinical visits as much as possible. Dr. Baum highlights a secondary motivator for the increased use of telemedicine: there is a shortage of urologists, particularly in rural areas, which can be addressed with telemedicine. Conventional wisdom used to hold that older patients were not amenable to telemedicine because of technology barriers. Dr. Baum introduces solutions, including triangulation, in which telemedicine is facilitated by having a third person in the room. He also explains how to prepare senior patients for these visits, as well as his six steps for creating a successful virtual visit. He notes that it is imperative that the instructions are short, to the point, and easy to follow. Finally, Dr. Baum emphasizes the importance of soliciting feedback on the experience from patients to improve their experience.

Integrating MRI and Molecular Markers to Detect Aggressive Prostate Cancer

Posted by Sanoj Punnen, MD, MAS | Apr 2020

Sanoj Punnen, MD, MAS, Associate Professor of Clinical Urology in the University of Miami Health System, describes how recent trial based research has supported the synergistic qualities of MRI and biomarkers in the cancer detection process by reducing unnecessary biopsies by approximately 25%. He notes that more research is needed to declare an ideal procedure as well as what biomarkers are most efficient. Introducing MRI reading AI by the name Habitat Risk Scoring System, he highlights his own research which could alter how MRIs are processed and increase NPV to 92% without the use of biopsy.

Interim Analysis for Patterns of Erectile Recovery After Robotic‐Assisted Laparoscopic Prostatectomy: A Penile Rehab Study

Posted by Helal Syed, MD | Apr 2020

Helal Syed, MD, a urology resident at Brooke Army Medical Center in San Antonio, Texas, discusses investigating the use of pentoxifylline versus PDE-5 inhibitors (PDE-5i) in a small case-control study in patients undergoing robotic-assisted laparoscopic prostatectomy (RALP). He notes the high cost of PDE-5i, which accounted for nearly $82 million of healthcare-related spending in 2015, and how medications such as pentoxifylline could help improve postoperative ED while reducing costs. Finally, Dr. Syed discusses the results of a 17 patient case-control study using pentoxifylline and PDE-5i, which demonstrated no difference in IIEF scores, BMI, or stretched penile length between the treatment groups.